Case Study 1

No News?

Positioning the Expert: The Scientist 

The founding scientist of biotech start up working in Alzheimer’s disease had a contrarian view on the causes of the disease. We discovered this during orientation, and decided to establish him with key medical and science writers as the outsider voice in the Alzheimer’s causation debate—a heated discussion as it determines therapeutic pathways.

Results:

The Chief Scientific Officer of this company gained visibility as a leading dissenting voice among scientists in this field. The company’s technology flowed from this contrarian view, so this difference formed an essential part of understanding how they could fulfill their claims. Finally, the science coverage spilled over into high visibility coverage for a major company milestone that otherwise would just have made the trades, if that.

How We Did It:

Accordingly, we got the Chief Scientific Officer of a bulletin board company with no product quoted in the WALL STREET JOURNAL on multiple stories

 

Wall Street Journal

No matter what a man is told in the society they are valued in part by what they can do it, cheapest price for levitra then Magic Power Coffee can also. cialis no prescription uk One option is to take drivers’ education at local public schools or at local driving schools that offer private instruction and classes. For a long time, many people have found that sexual activity is much more important then they ever imagined – when they have to do without it, that is. viagra viagra sildenafil These vessels get it extremely hard to take blood to spongy tissues in the shaft of penile organ and in patients with Peripheral Vascular disease the blood flow to the legs is drastically reduced or in fact in some cases, there viagra 100 mg heritageihc.com were very minimal blood supply.

 CS1Clip1HeadlineCS1Clip2Headline


He also was profiled in a major feature in the Boston Globe science section.

Boston Globe


Getting the CSO known among pharmaceutical writers led to interest in a company licensing deal, that was covered exclusively in the Wall Street Journal.
Wall Street Journal

Leave a Reply

Your email address will not be published. Required fields are marked *